ReviewJournal of cellular and molecular medicine2018
Endocannabinoid-related compounds in gastrointestinal diseases.
Review in Journal of cellular and molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Effectiveness of THC-containing cannabis for inflammatory bowel disease: a systematic review.Journal of cannabis research · 2026Pooled it
- A systematic review on gut microbiota in type 2 diabetes mellitus.Frontiers in endocrinology · 2024Pooled it
- The Role of Genetically Engineered Probiotics for Treatment of Inflammatory Bowel Disease: A Systematic Review.Nutrients · 2023Pooled it
- Cyclic Vomiting Syndrome in Children.Frontiers in neurology · 2020Pooled it
- Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption.Frontiers in endocrinology · 2021Trial
- WIN55,212-2 attenuates intestinal fibrosis in a DSS-induced mouse model.Pharmacological reports : PR · 2026Article
- FMT and TCM to treat diarrhoeal irritable bowel syndrome with induced spleen deficiency syndrome- microbiomic and metabolomic insights.BMC microbiology · 2024Article
- Next-Generation Probiotics for Inflammatory Bowel Disease.International journal of molecular sciences · 2022Review
- Cannabidiol (CBD) in Cancer Management.Cancers · 2022Review
- Mutual Links between the Endocannabinoidome and the Gut Microbiome, with Special Reference to Companion Animals: A Nutritional Viewpoint.Animals : an open access journal from MDPI · 2022Review
- Migraine and Its Equivalents: What Do They Share? A Narrative Review on Common Pathophysiological Patterns.Life (Basel, Switzerland) · 2021Review
- EngineeredInternational journal of molecular sciences · 2021Article
- Cannabinoid Receptors Overexpression in a Rat Model of Irritable Bowel Syndrome (IBS) after Treatment with a Ketogenic Diet.International journal of molecular sciences · 2021Article
- A Palmitoylethanolamide ProducingFrontiers in pharmacology · 2021Article
- Impact of Circulating N-Acylethanolamine Levels with Clinical and Laboratory End Points in Hemodialysis Patients.American journal of nephrology · 2021Article
- Cannabis and Autoimmunity: Possible Mechanisms of Action.ImmunoTargets and therapy · 2021Review
- Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases.International journal of molecular sciences · 2020Review
- Cannabidiol primer for healthcare professionals.Proceedings (Baylor University. Medical Center) · 2020Review
- Palmitoylethanolamide and Related ALIAmides: Prohomeostatic Lipid Compounds for Animal Health and Wellbeing.Veterinary sciences · 2020Review
- Ethnic differences in genetic polymorphism associated with irritable bowel syndrome.World journal of gastroenterology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The endocannabinoid system (ECS) is an endogenous signalling pathway involved in the control of several gastrointestinal (GI) functions at both peripheral and central levels. In recent years, it has become apparent that the ECS is pivotal in the regulation of GI motility, secretion and sensitivity, but endocannabinoids (ECs) are also involved in the regulation of intestinal inflammation and mucosal barrier permeability, suggesting their role in the pathophysiology of both functional and organic GI disorders. Genetic studies in patients with irritable bowel syndrome (IBS) or inflammatory bowel disease have indeed shown significant associations with polymorphisms or mutation in genes encoding for cannabinoid receptor or enzyme responsible for their catabolism, respectively. Furthermore, ongoing clinical trials are testing EC agonists/antagonists in the achievement of symptomatic relief from a number of GI symptoms. Despite this evidence, there is a lack of supportive RCTs and relevant data in human beings, and hence, the possible therapeutic application of these compounds is raising ethical, political and economic concerns. More recently, the identification of several EC-like compounds able to modulate ECS function without the typical central side effects of cannabino-mimetics has paved the way for emerging peripherally acting drugs. This review summarizes the possible mechanisms linking the ECS to GI disorders and describes the most recent advances in the manipulation of the ECS in the treatment of GI diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.